Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Therapeutic cancer vaccines on trial

Nature Biotechnology volume 20, pages 659–663 (2002)Cite this article

Therapeutic cancer vaccines offer hope for patients for whom traditional treatments have failed, but various obstacles may impede the launch of these new agents.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Clinical trials of cancer vaccines initiated annually between 1985 and 2001.

© Amy Center

References

  1. Edwards, B.K. et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on US cancer burden. Cancer 94, 2766–2792 (2002).

    Article  PubMed  Google Scholar 

  2. Armstrong, A.C. et al. Science, medicine, and the future: Cellular immunotherapy for cancer. BMJ 323, 1289–1293 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dalgleish, A.D. Cancer vaccines. Br. J. Cancer 82, 1619–1624 (2000).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Armstrong, A.C. & Hawkins, R.E. Vaccines in oncology: background and clinical potential. Br. J. Radiol. 74, 991–1002 (2001).

    Article  CAS  PubMed  Google Scholar 

  5. Durrant, L.G. Cancer vaccines. Anticancer Drugs 8, 727–733 (1997).

    Article  CAS  PubMed  Google Scholar 

  6. Pardoll, D.M. Cancer vaccines. Nat. Med. 4, 525–531 (1998).

    Article  CAS  PubMed  Google Scholar 

  7. Timmerman, J.M. & Levy, R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50, 507–529 (1999).

    Article  CAS  PubMed  Google Scholar 

  8. Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4, 110–118 (2002).

    CAS  PubMed  Google Scholar 

  9. Kaitin, K.I. & Healy, E.M. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. Drug Inf. J. 34, 1–14 (2000).

    Article  Google Scholar 

  10. Reichert, J.M. et al. The effects of the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act on the development and approval of therapeutic medicines. Drug Inf. J. 35, 85–94 (2001).

    Article  Google Scholar 

  11. Chung, K.-T. & Biggers, C.J. Albert Léon Charles Calmette (1863–1933) and the antituberculous BCG vaccination. Perspect. Biol. Med. 44, 379–389 (2001).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Funding for this work was provided in part by a grant from the Drug Information Association (Fort Washington, PA).

Author information

Authors and Affiliations

  1. senior research fellow and Cherie Paquette is research assistant at the Tufts Center for the Study of Drug Development, Boston, MA

    Janice M. Reichert & Cherie Paquette

Authors
  1. Janice M. Reichert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cherie Paquette
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reichert, J., Paquette, C. Therapeutic cancer vaccines on trial. Nat Biotechnol 20, 659–663 (2002). https://doi.org/10.1038/nbt0702-659

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0702-659

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing